Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10

Phase 1CompletedNCT00000345

National Institute on Drug Abuse (NIDA)

Overview

The purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Conditions

Opioid-Related Disorders

Interventions

LofexidineDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Locations (1)

Friends Research Institute

Los Angeles, California, United States

Outcomes

Primary Outcomes

Opiate withdrawal

Adverse effect measures

Craving of opiates

Liking of opiates

Efficacy of lofexidine

Euphoria

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.